CG
MYGN icon

Clinton Group’s Myriad Genetics MYGN Stock Holding History

Clinton Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-24,516
Closed -$471K – 767
2017
Q1 		$471K Sell
24,516
-19,294
-44% -$342K 0.03% 644
2016
Q4 		$730K Sell
43,810
-2,235
-5% -$40.4K 0.04% 470
2016
Q3 		$948K Sell
46,045
-130,158
-74% -$3.3M 0.04% 507
2016
Q2 		$5.39M Buy
+176,203
New +$6.12M 0.24% 109

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Clinton Group's MYGN Position: Q2 2017 in Review

Clinton Group sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 24,516 shares — an estimated $471K sold.

Clinton Group first reported a position in MYGN in Q2 2016 and held it in 4 quarters. The position peaked at $5.39M in Q2 2016. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

  • Clinton Group reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
  • Clinton Group sold 24,516 Myriad Genetics shares in Q2 2017, an estimated $471K.
  • Clinton Group first reported a position in Myriad Genetics in Q2 2016 and held it in 4 quarters.
  • Clinton Group's Myriad Genetics position peaked at $5.39M in Q2 2016.
  • 239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Clinton Group's 13F filing for Q2 2017, filed 14 Aug 2017.